Sort By

  • Newest

  • Newest

  • Oldest

  • Author Name

  • Author Name

  • David Chaplin

  • Drew Meredith

  • Giselle Roux

  • Greg Bright

  • Ishan Dan

  • James Dunn

  • Lachlan Maddock

  • Owen Raszkiewicz

After watershed year for biotechs, diversification is key

2020 was a watershed year for biotech companies around the world. The combination of urgent need, commitment and massive government support saw the huge benefits of research and development on show, when not one but multiple companies produced vaccines for the Coronavirus. Extensive coverage of the sector generated huge enthusiasm for it, with many stocks…
Staff Writer | 10th Mar 2021 | More
Biotech BARD1 cancer detection treatment gaining traction

BARD1 Life Sciences (ASX: BD1) – Earlier in the week, the Inside Investor team published an article on BARD1 Life Sciences (click here) and its meteoric rise following a positive announcement on ovarian cancer detection. Shares have risen from 74.5c on the day of the announcement to $3.20 at the time of writing. That’s a…
Ishan Dan | 17th Feb 2021 | More
Thinking forward: Three ASX biotech stars

And still they keep coming – here’s the fifth instalment of our series on the fascinating ASX cohort of medical device developers. As always, don’t let the impressive sexiness of the technology persuade you on its own that these stocks are headed for the stars. In each of the three cases presented here, previous investors…
James Dunn | 28th Oct 2020 | More